media – Page 11 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Kangle Guard’s operating income in 2024 fell by 50.2%, and its losses expanded to 357 million yuan

On April 29, Kangle Guard (833575) announced its 2024 annual report. The company’s operating income was 890,000 yuan, a year-on-year decrease of 50.2%; the net profit attributable to the parent company changed from a loss of 301 million yuan in the same period last year to a loss of 357 million yuan, and the loss amount further expanded; the net profit attributable to the parent company after deducting non-recurring items changed from a loss of 314 million yuan in the same period last year to a loss of 363 million yuan, and the loss amount further expanded; the net operating cash flow was -125 million yuan, a year-on-year increase of 30.7%; EPS (fully diluted) was -1.2693 yuan. In the fourth quarter, the company’s operating income was 270,000 yuan, up 49.9% year-on-year; the net profit attributable to the parent company changed from a loss of 76.04 million yuan in the same ...
- Source: drugdu
- 60
- May 1, 2025
Stem cell therapy leads the transformation of Japanese medicine

In 2006, stem cell scientist Shinya Yamanaka was awarded the 2012 Nobel Prize in Physiology or Medicine for reprogramming adult cells into induced pluripotent stem cells (iPS cells). Based on this achievement, researchers across Japan are cultivating cells into retinal strips, myocardial slices, or neuronal clusters in order to treat blindness, repair the heart, and reverse neurodegenerative diseases. Early clinical trials suggest that these cells may indeed be useful for treating different conditions such as Parkinson’s disease or spinal cord injury. Now, after nearly two decades of arduous efforts and numerous setbacks, Japan hopes to bring these therapies to the market. According to the journal Nature, there are over 60 ongoing clinical trials of iPS cells worldwide, with nearly one-third conducted in Japan. Clinical breakthrough in eye diseases In 2014, ophthalmologist Masahiro Takahashi from Kobe Eye Hospital first used cells derived from iPS cells to treat macular degeneration. She extracted ...
- Source: drugdu
- 88
- April 30, 2025
Ruizhi Pharmaceutical’s loss in 2024 was reduced to 226 million yuan, and its operating income fell by 14.8%

On April 28, Ruizhi Pharmaceutical (300149) announced its 2024 annual report. The company’s operating income was 970 million yuan, a year-on-year decrease of 14.8%; the net profit attributable to the parent company changed from a loss of 908 million yuan in the same period last year to a loss of 226 million yuan, and the loss amount decreased; the net profit attributable to the parent company after deducting non-recurring items changed from a loss of 911 million yuan in the same period last year to a loss of 236 million yuan, and the loss amount decreased; the net operating cash flow was 168 million yuan, a year-on-year increase of 11.4%; EPS (fully diluted) was -0.4548 yuan. In the fourth quarter, the company’s operating income was 252 million yuan, a year-on-year decrease of 13.9%; the net profit attributable to the parent company changed from a loss of 867 million yuan in ...
- Source: drugdu
- 69
- April 30, 2025
Renmin Pharmaceutical’s revenue in 2024 is 25.435 billion yuan, and the controlling shareholder’s reorganization is about to be implemented

On the evening of April 28, Renmin Pharmaceutical disclosed its 2024 annual report. The company achieved operating income of 25.435 billion yuan for the whole year, a year-on-year increase of 3.71%; net profit attributable to the parent company was 1.33 billion yuan. The first quarter report on the same day showed that the company’s current operations continued to be stable, with operating income of 6.137 billion yuan; net profit attributable to the parent company was 540 million yuan, a year-on-year increase of 11.09%. In addition, the bankruptcy reorganization of the company’s controlling shareholder Contemporary Group is progressing smoothly. The announcement shows that the reorganization plan has been approved by the court. After the reorganization is implemented, China Merchants Group’s China Merchants Innovation and Technology may become a strategic investor in the listed company. The financial report shows that in 2024, Renmin Pharmaceutical’s net profit attributable to the parent company decreased ...
- Source: drugdu
- 65
- April 30, 2025
Tasly’s pharmaceutical industry revenue grew steadily in the first quarter

On the evening of April 28, Tasly (600535) released its first quarter report for 2025. During the reporting period, the company achieved pharmaceutical industry revenue of 1.842 billion yuan, a year-on-year increase of 1.83%. The company achieved a net profit of 314 million yuan attributable to its parent company in the first quarter, a year-on-year increase of 6.47%. In the first quarter, the company’s traditional Chinese medicine sector achieved revenue of 1.469 billion yuan, a year-on-year increase of 1.90%. On March 28, the company announced that the transfer and registration of shares between the original controlling shareholder Tasly Group and its concerted actors and China Resources Sanjiu and Guoxin Investment has been completed. China Resources Sanjiu became the company’s controlling shareholder, and the actual controller was changed to China Resources Co., Ltd. With the completion of the transaction, Tasly also announced major adjustments to the board of directors and the ...
- Source: drugdu
- 68
- April 30, 2025
Hualan Vaccine’s net profit attributable to the parent company in the first quarter was 32.78 million yuan, a year-on-year decrease of 15.1%

On April 27, Hualan Vaccine (301207) announced the first quarter report of 2025. The company’s operating income was 24.28 million yuan, a year-on-year decrease of 29.0%; the net profit attributable to the parent company was 32.78 million yuan, a year-on-year decrease of 15.1%; the net profit attributable to the parent company after deducting non-recurring items was 15.42 million yuan, a year-on-year increase of 8.9%; the net cash flow from operations was -2.59 million yuan, a year-on-year decrease of 102.7%; EPS (fully diluted) was 0.0545 yuan. As of the end of the first quarter, the company’s total assets were 7.443 billion yuan, a decrease of 1.1% from the end of the previous year; the net assets attributable to the parent company were 6.048 billion yuan, an increase of 0.6% from the end of the previous year. The company mainly focuses on the research and development, production and sales of biological vaccines, ...
- Source: drugdu
- 62
- April 30, 2025
A Comparative Analysis for Global Market Compliance

Drugdu.com expert’s response: CE, UL, and 3C certifications represent distinct certification systems tailored to different markets and standards, with notable differences in scope, certification authorities, testing criteria, processes, and marking requirements. Below is a detailed comparison: I. CE Certification: The “Legal Passport” for the EU Market 1. Fundamental Attributes Legal Mandate: In the EU, the CE mark is a legal requirement for product commercialization—akin to a driver’s license for operating a vehicle. Absence of the mark constitutes a violation. Liability Traceability: Manufacturers must self-declare compliance via technical documentation (risk analysis, test reports, design drawings) and a signed Declaration of Conformity (DoC). EU customs authorities retain traceability to the responsible party. Risk-Tiered Compliance: Low-Risk Products (e.g., general-purpose sockets): Self-declaration under EU harmonized standards (e.g., EN 60884) with 10-year record retention. High-Risk Products (e.g., in vitro diagnostic medical devices): Mandatory type testing and factory audits by EU Notified Bodies (e.g., BSI, DEKRA), with certification ...
- Source: drugdu
- 75
- April 30, 2025
Multiple positive factors combined with the pharmaceutical themed fund ‘hardship over sweetness’

At the end of the first quarter of this year, several active equity funds with heavy holdings in the humanoid robot sector were still far ahead in performance, while recently, funds with heavy holdings in the innovative medicine sector have stood out. As of April 27th, the Huitianfu Hong Kong Advantage Selection Hybrid (QDII) A managed by fund manager Zhang Wei has become the best performing public offering product of the year with a return rate of 64.44%. Industry insiders have stated that compared to the past, the market for innovative drugs in this round is more rational. Firstly, the industry trends and policy guidance have become clearer, leading to an increase in market confidence; Secondly, many key companies’ core products have already been listed or validated with critical clinical data, resulting in a significant increase in investment success rates; Thirdly, some leading companies are about to cross the ...
- Source: drugdu
- 80
- April 29, 2025
The new version of the National Health Supervision and Inspection Plan has been released, which for the first time explicitly targets online “medical trusts”

NO.1 clarifies for the first time to crack down on online “medical trusts” The National Center for Disease Control and Prevention and three other departments recently jointly released the “2025 National Random Supervision and Sampling Plan” for the medical and health field. Compared with the 2024 plan, the 2025 plan will make adjustments in the scope of supervision, add new areas of supervision such as Internet diagnosis and treatment, mental health, and for the first time explicitly crack down on new illegal behaviors such as online “medical care”, further strengthen the governance of public health and medical order. Comment: The clear crackdown on online “medical trusts” in regulation is a powerful upgrade to medical supervision. The concealment of online “medical care” is strong, seriously disrupting medical order and damaging patient rights. It is expected to purify the medical network space with the supervision of new fields such as Internet ...
- Source: drugdu
- 75
- April 29, 2025
Hualan Vaccine’s net profit attributable to the parent company in the first quarter was 32.78 million yuan, a year-on-year decrease of 15.1%

On April 27, Hualan Vaccine (301207) announced the first quarter report of 2025. The company’s operating income was 24.28 million yuan, a year-on-year decrease of 29.0%; the net profit attributable to the parent company was 32.78 million yuan, a year-on-year decrease of 15.1%; the net profit attributable to the parent company after deducting non-recurring items was 15.42 million yuan, a year-on-year increase of 8.9%; the net cash flow from operations was -2.59 million yuan, a year-on-year decrease of 102.7%; EPS (fully diluted) was 0.0545 yuan. As of the end of the first quarter, the company’s total assets were 7.443 billion yuan, a decrease of 1.1% from the end of the previous year; the net assets attributable to the parent company were 6.048 billion yuan, an increase of 0.6% from the end of the previous year. The company mainly focuses on the research and development, production and sales of biological vaccines, ...
- Source: drugdu
- 92
- April 29, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.